Alshafie W, Chappe FG, Li M, Anini Y, Chappe VM. VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1-and PKCε-dependent manner.
cystic fibrosis transmembrane conductance regulator; vasoactive intestinal peptide; protein kinase C epsilon; Na ϩ /H ϩ exchange factor 1; cystic fibrosis associated ligand; ezrin/radixin/moesin THE CYSTIC FIBROSIS TRANSMEMBRANE conductance regulator (CFTR) is a tightly regulated ion channel that mediates cAMP-stimulated anion conductance in epithelia and other cell types (18) . Very little is known about its threshold level that is functionally necessary to maintain healthy lungs and a normal phenotype. Oxidative stress induced by cigarette smoke or ozone exposure inhibits chloride and glutathione secretions by reducing the amount of CFTR at the apical surface of epithelial cells (9, 10) . Also, mutations resulting in the absence or dysfunction of CFTR from the apical membrane of epithelial cells are responsible for the development cystic fibrosis (CF), the most common lethal genetic disease among the Caucasian populations (23) . CF is characterized by reduced chloride secretion across epithelia, viscous mucus secretions, chronic bacterial infections, and inflammation of the airways (55) . On the other hand, hyperstimulation of the CFTR channels such as during bacterial infection of the intestine by Vibrio cholerae may result in secretory diarrhea, dehydration, acidosis, and death (54) .
To function as a chloride channel CFTR requires apical membrane localization. However, it is mostly present in recycling endosomes forming an important submembrane pool of mature proteins (6) . CFTR has a relatively long half-life (16 -24 h) but a rapid turnover, although variable among cell types at 2-16%/min (11, 42, 53) . It is internalized by clathrin-coated vesicles due to the presence of dileucine and tyrosine endocytotic signals in its C-terminal that interact with the clathrine adapter complex AP-2 to enter the clathrin-coated pits (2, 29, 43) . CFTR also interacts with actin-binding proteins to recycle back to the plasma membrane via recycling endosomes (45) .
Several scaffolding proteins with PDZ domains play a role in CFTR membrane insertion and stability (25) . CFTR C-terminal interacts with CFTR associated ligand (CAL) and Na ϩ /H ϩ exchange regulatory factor-1 (NHERF1) (16, 51) . Although CAL binding to CFTR promotes its targeting to lysosomal degradation, NHERF1 helps maintain CFTR at the cell membrane in close vicinity to receptors and kinases by tethering to the actin cytoskeleton (15, 16, 32) . Structural studies showed that CAL and NHERF1 compete for the same binding site in CFTR C-terminal to regulate the steady-state level of mature CFTR at the cell's surface. NHERF1 also contains a binding domain to ezrin/radixin/moesin (ERM), another cross-linker protein complex involved in maintaining CFTR at the cell membrane by anchoring itself to the actin cytoskeleton (7, 47) . The ERM complex is inactive in the cytoplasm and upon phosphorylation on serine and threonine residues, it translocates to the cell surface where it exerts its linking activity (27) . RhoA kinase and PKC phosphorylate ERM.
There are conflicting results on the signaling cascades involved in CFTR recycling, probably because of disparity in cells studied. Both protein kinases A (PKA)-and C (PKC)-dependent mechanisms have been reported. Although direct phosphorylation of its regulatory domain by protein kinases A and C is a prerequisite for the ATP-dependent gating of the CFTR chloride channel, a PKC-dependent permissive and enhancing effect on CFTR-dependent chloride secretion in epithelial cells is also attributed to an increase in the number of functional CFTR channels in the apical membrane (4, 5, 11) . The mechanism of CFTR endo-and exocytosis has been studied in some detail, but its regulation by physiological agonists is less well understood and seems to be cell-type dependent.
Most studies of CFTR regulation by PKC have used purified kinases or artificial activators rather than physiological secretagogues. In airway submucosal glands and other exocrine tissues, the neuropeptide vasoactive intestinal peptide (VIP) is the major physiological activator of CFTR-dependent secretion by serous cells (57) , which contributes to mucus hydration and local innate defense. VIP is released from nerves surrounding the airways where it performs several functions, including the control of inflammation, relaxation of smooth muscle, and regulation of CFTR chloride channels. Although initially considered as a cAMP-mediated secretagogue, VIP regulates CFTR through both PKA-and PKC-dependent signaling pathways (1, 31) . VIP plays a significant role in apical CFTR insertion in several in vivo preparations and in cell lines, implicating either PKA or PKC signaling depending on the kind of epithelium considered (3, 4, 33) . In the human bronchial serous cell line Calu-3, we have demonstrated that prolonged stimulation by VIP stabilizes CFTR at the cell surface by reducing its internalization rate by more than 50% (11) . VIP regulation involves the recycling of mature CFTR proteins by the activation of VPAC1 receptors, G ␣i/q proteins, and PKC signaling cascade.
Here, we extend our study of the signaling cascade by which prolonged VIP stimulation of Calu-3 cells increases CFTR membrane expression and function. We have identified PKCε, NHERF1, and P-ERM as part of the VIP mechanism of action.
MATERIALS AND METHODS

Chemicals.
Cell culture media and supplements were purchased from GIBCO (Invitrogen, Burlington, ON, Canada) or Sigma (St. Louis, MO). The following antibodies were used: MAb mouse anti-NHERF1 and polyclonal rabbit anti-CAL were from Santa Cruz Biotechnology (Santa Cruz, CA). MAb anti-CFTR (M3A7) was from Millipore Canada (Toronto, ON, Canada). Polyclonal rabbit anti-P-ERM and polyclonal rabbit anti-NHERF1 were from Cell Signaling Technology (Danvers, MA). Mouse MAb anti-GAPDH-horseradish peroxidase conjugated was from Sigma. Rabbit polyclonal secondary IgG conjugated to Dylight 650 was from Abcam (Cambridge, MA). Goat anti-mouse secondary IgG conjugated to peroxidase as well as goat anti-mouse secondary IgG conjugated to either Cy5 or Cy3 were from Jackson ImmunoResearch (West Grove, PA). ERM siRNAs (h), NHERF-1 siRNAs (h) as well as the nontargeting scrambled siRNAs (negative control) were from Santa Cruz Biotechnology. ECLϩ chemiluminescence detection kits were from BioRad (Hercules, CA). Vectashield mounting media for fluorescence was from Vector Laboratories (Burlingame, CA). Protease inhibitor cocktail was from Roche (Laval, QC, Canada). Other chemicals were from Sigma and of the highest grade available.
Cell culture. Calu-3 cells were cultured in ␣-minimum essential medium supplemented with 15% FBS, 1% penicillin-streptomycin, 1% nonessential amino acids, and 1% sodium pyruvate with 5% CO 2 at 37°C.
Immunostaining and confocal microscopy. Calu-3 cells were plated on glass coverslips at low density and maintained in culture at 37°C before treatment with 300 nM VIP or 20 nM phorbol 12-myristate 13-acetate (PMA) as indicated on individual figures. As described in detail elsewhere (46) , cells were fixed with 10% TCA before incubation with anti-P-ERM antibody to maintain phosphorylation, or with 2% paraformaldehyde for all the other antibodies, before permeabilization and blocking with 0.1% Triton X-100/2% BSA solution. For single labeling, cells were incubated with one primary antibody [anti-CFTR antibody M3A7 (1:1,000), anti-NHERF1 (1:1,000), anti-PIST (1:600), or anti P-ERM (1: 100)] overnight at 4°C, washed and incubated with the corresponding secondary antibody conjugated to either Cy3 (1:100), Cy5 (1:200) or Dylight 650 (1:100) for 2 h at room temperature (RT), and washed again before mounting. For double labeling, 2-h incubation at RT temperature with the first primary antibody was followed by a corresponding secondary (1 h) before washing and incubation with another primary antibody overnight at 4°C. Cells were then washed again and incubated with the corresponding second secondary antibody for 1 h at RT before final washes. All slides were mounted, allowed to dry at RT for 30 min, sealed with nail polish and stored at Ϫ20°C. Negative controls were performed by omitting the primary antibody. Confocal microscopy was performed with a Zeiss LSM 510 Meta confocal microscope (CMDI Facility, Faculty of Medicine, Dalhousie University).
The colocalization of CFTR with the membrane marker CM-Dil or with other proteins was quantified with image J software using an image analysis protocol described before (50) . Briefly, images for individual proteins were first converted into binary images. The binarized images were then multiplied at 50% intensity such that pixels remained white when the proteins colocalized and turned gray when they did not colocalize. The noncolocalized gray pixels were segregated using the difference function and measured. The percentage of the white colocalized pixels relative to the total of white and gray was then calculated. For these analyses, 10 cells per condition and 3 different experiments in each condition were analyzed.
Immunoblotting. Calu-3 cells forming confluent monolayers on 10-cm Petri dishes were washed three times with ice-cold PBS, harvested by scraping, and lysed on ice for 30 min in RIPA buffer supplemented with a protease inhibitor cocktail as described earlier (11) . Lysates were centrifuged to eliminate cell debris. The supernatant was collected and assayed for protein concentration using the quick start Bradford protein assay (BioRad). Proteins (20 -40 g) were subjected to 7.5% SDS-PAGE, transferred to a PVDF membrane, and saturated in 5% milk/TTBS buffer before incubation with a primary antibody [anti-CFTR M3A7 (1/1,000); anti-NHERF1 (1/ 2,000); anti-CAL (1/600) or anti P-ERM (1/100) overnight at 4°C] and with corresponding secondary antibody (goat anti-mouse for CFTR and NHERF1 or goat anti-rabbit for CAL and P-ERM) conjugated with horseradish peroxidase and detected by chemiluminescence. To detect GAPDH content in immunoblotted samples, PVDF membranes were stripped (Thermo-Fisher stripping buffer) and reprobed with anti-GAPDH conjugated to horseradish peroxidase. Protein expression levels were compared by densitometry of scanned Western blots using ImageJ software NIH (http://rsb.info.nih.gov/ij/). Values were normalized to their corresponding GAPDH signals and expressed as percentage of control samples from the same immunoblot.
siRNA electroporation. 60 -80% confluent Calu-3 cell monolayers (in 6-cm Petri dish) were collected by trypsinization, resuspended in 2 ml siRNA transfection media, and centrifuged at 1,200 rpm for 5 min. Cells (10 ϫ 10 7 ) were then resuspended in 100 l transfection mixture containing 80 pmol siRNA and an equal volume of transfection reagent in 100 l of transfection medium. The transfection mixture was transferred to 2-mm electroporation cuvette and electroporated using ECM 830 electroporator by a single pulse (20 ms) at 310 V. Cells were then immediately diluted in culture media prewarmed to RT and incubated at 37°C for 48 h before assay. Preliminary experiments were performed with fluorescein conjugated control siRNA to optimize the electroporation parameters until reaching 60 -70% survival and 40 -50% transfection rates. Also, the highest level of NHERF1 and ERM downregulation was observed 48 h after electroporation. Targeting siRNAs consisted of pools of 3 to 5 target-specific 19-to 25-nt siRNAs.
In situ proximity ligation assays. In situ interactions were detected using the Duolink In Situ proximity ligation assays (PLA) detection kit (Sigma-Aldrich) containing the PLA probe anti-rabbit minus, PLA probe anti-mouse plus, Detection Kit Orange, and following the manufacturer's instructions. Calu-3 cells were cultured on glass coverslips at low density for 48 h before treatment (or not) with 300 nM VIP directly added to the cell culture medium for 30 min at 37°C. The culture medium was then removed, and cells were washed three times in PBS and fixed with either 2% paraformaldhyde buffer for 20 min at RT or with 10% TCA for 15 min on ice for P-ERM labeling. Cells were then permeabilized in antigen-blocking solution containing 0.1% Triton X-100 and 2% BSA for 45 min at RT with gentle shaking and incubated overnight at 4°C in PBS/0.1% Triton X-100/0.2% BSA with the two primary antibodies raised against the two proteins of interests, each from a different host species. The primary antibodies were then removed, and cells were washed with PBS/0.1% Triton X-100/0.2% BSA three times for 10 min each with gentle agitation. The cells were incubated with the mouse/rabbit PLA probes preparation for 60 min at 37°C, washed with wash buffer A twice with gentle agitation, and incubated with the ligation mixture for 30 min at 37°C and washed again. Cells were incubated with the amplification mixture for 100 min at 37°C, protected from light. After final washes in buffer B, cells were mounted using Duolink in situ mounting medium with DAPI, sealed with nail polish, and allowed to dry for 15 min at RT before imaging using a fluorescence microscope (Zeiss Axiovert 200M).
Iodide effluxes. Control, untreated, or electroporated cells were plated into 35 mm dishes for 48 h prior to experiment as described earlier (11) . Briefly, cells were incubated with iodide loading buffer [in mM: 136 NaI, 3 KNO 3, 2 Ca (NO3), 11 glucose, and 20 HEPES; pH 7.4] for 1 h at RT. Extracellular NaI solution was then removed and rapidly replaced with efflux buffer in which NaI was replaced with NaNO 3. Samples were taken and replaced at 1-min intervals. The first three samples were used to establish a stable efflux baseline. Cells were stimulated with a cAMP cocktail containing: 150 M cptcAMP, 1 mM IBMX, and 10 M forskolin, from 0 to 10 min. Where indicated, VIP pretreatment was made by adding 300 nM VIP directly into the iodide loading buffer for 1 h. The iodide concentration of each sample (nmol·ml Ϫ1 ·min Ϫ1 ) was determined using an iodide-sensitive electrode (Thermo Electron) moved over each sample by a computerized autosampler and values plotted vs. time (Efflux Analysis Software, F. Chappe and V. Chappe, 2007) . From these plots, the I Ϫ efflux rate constant k (min Ϫ1 ) was calculated at every minute interval according to Becq et al. (5) .
Statistics. Results are reported as means Ϯ SE, n ϭ number of independent experiments. Differences were assessed using the Student's t-test or ANOVA (OriginePro 8), with P Յ 0.05 considered significant.
RESULTS
VIP-dependent increase in CFTR membrane localization involves PKC.
Among the 11 known PKC isoforms, the calcium-independent novel isoform epsilon (PKCε) was identified as the exclusive isoform involved in regulating CFTR activity in Calu-3 cells and in mediating VIP-dependent increase in CFTR membrane density in other cell types (11, 39) . In immunolocalization experiments and confocal microscopy analysis, CFTR signal was found both intracellularly and at the membrane of untreated Calu-3 cells (Fig. 1, A and B) . A marked increase in membrane CFTR signal was visible after 30 min of incubation with VIP (300 nM), a treatment that was previously found to increase membrane CFTR density in biotinylation assays (11) . Membrane vs. intracellular CFTR localization was confirmed by the overlapping signals for CFTR and the CM-Dil membrane dye (Fig. 1B) . Quantification of the percentage of green pixels (CFTR immunostaining) that colocalized with the red pixels (CM-Dil) indicated that 27.22 Ϯ 1.59% of the signal represents CFTR proteins localized at the cell membrane of untreated Calu-3 cells (Fig. 1D) . After VIP treatment, the amount of CFTR proteins inserted into the cell membrane doubled (60.62 Ϯ 4.27%).
We previously reported that PKCε was involved in VIPdependent increase in F508del-CFTR membrane stability in the human nasal epithelial cells JME/CF15 (1, 46) . Here we used the cell-permeant PKCε inhibitor peptide EAVSLKPT to demonstrate the role of this isoform in VIP signaling cascade responsible for increase in CFTR membrane expression. When cells were preincubated with the PKCε inhibitor peptide (15 M) for 30 min before VIP treatment, CFTR localization was similar to what was observed in control untreated cells, and the VIP effect was lost (Fig. 1, A and B) .The percentage of green pixels (CFTR immunostaining) that colocalized with the red pixels (CM-Dil) was not significantly different than that measured in control cells (34.34 Ϯ 6.95%, P ϭ 0.272).
No changes in the total amount of fully mature CFTR proteins (ϳ180 kDa) were observed after stimulating cells with VIP or inhibiting PKCε (Fig. 1C) , indicating no effect on CFTR maturation. This is consistent with the reported role of VIP in reducing the rate of CFTR endocytosis (11) .
VIP stimulation increases NHERF1 and CFTR colocalization and interaction. NHERF1 is a PDZ domain-containing scaffolding protein known to interact with CFTR C-terminal PDZ domain to stabilize it at the cell membrane. We investigated if VIP could induce an increase in CFTR and NHERF1 interaction. As seen in Fig. 2 , VIP stimulation of Calu-3 cells induces an increase in NHERF1 signal at the cell membrane and strong colocalization with CFTR (Fig. 2, A and B) . CFTR immunostaining signal (red pixels) (39.83 Ϯ 3.03%) overlapped with NHERF1 (green pixels) in control cells, whereas VIP stimulation increased the overlapping to 72.79 Ϯ 4.78% (Fig. 2, F and G) .
NHERF1 siRNA confirms this result. Specific NHERF1 siRNA induced a significant reduction in NHERF1 protein expression level (38.2 Ϯ 3.9%, P Ͻ 0.003, 48 h after transfection) as measured by densitometry of scanned immunoblots without any change in CFTR expression level or maturation (Fig. 2, B and C) . Confocal microscopy analysis confirmed that the electroporation and the use of scrambled noncoding siRNAs did not affect CFTR cellular distribution or VIP-dependent increase in membrane CFTR. Although the survival rate in control experiments with fluorescently labeled noncoding siRNAs was high (60 -80%), only 40 -60% of all cells could effectively be transfected with this method (data not shown), resulting in a 40% reduction in protein expression when measured in immunoblots of total cell lysates. Because this reduction percentage reflects a mixed population of transfected and untransfected cells, to investigate the effect of ERM or NHERF1 downregulation in VIP mechanism, we selected cells that were positively transfected with NHERF1 siRNA, as confirmed by very low to no NHERF1 immunostaining signal (Fig. 2E) . The absence of NHERF1 in Calu-3 cells did not compromise CFTR localization but only reduced it slightly compared with control cells. Also, staining of nuclei and cytokeratin showed that cells with no or low NHERF1 signal, after siRNA transfection, were not morphologically different from control cells. However, VIP stimulation failed to increase CFTR membrane localization in NHERF1-siRNA-transfected cells, indicating the involvement of NHERF1 in VIP signaling cascade (Fig. 2, D and F) .
Furthermore, to confirm the interaction between CFTR and NHERF1 after VIP stimulation, we used the in situ PLA (Fig.  6) . We labeled fixed Calu-3 cells with a mouse anti-hCFTR and a rabbit anti-hNHERF1 as primary antibodies and their corresponding secondary antibodies. With this method, a fluorescent signal is only generated when the plus and minus probes attached to each secondary antibody are bound; only interacting proteins (closer than 40 nm) are detected by fluorescence microscopy. DAPI was used to identify cells' nuclei. As seen in Fig. 6A , a few fluorescence dots are visible in control cells representing the basal level of CFTR and NHERF1 interaction. However, after VIP stimulation of Calu-3 cells for 30 min, a very strong increase in red fluorescence dots was visible, indicating a strong increase in CFTR and NHERF1 in situ interactions.
VIP stimulation reduces CFTR/CAL interaction. Structural studies indicate that CAL and NHERF1 regulate the steadystate level of mature CFTR at the cell surface by competing for the same C-terminal binding site. Part of this regulation involves activated PKCε (16, (37) (38) (39) . We thus examine CFTR and CAL intracellular colocalization before and after VIP treatment. Figure 3E shows endogenous CAL expression in Calu-3 cells by immunoblotting. Three main isoforms were identified at ϳ34 and ϳ55, and ϳ60 kDa. As shown in Fig. 3A , most of the intracellular CFTR signal that was found to colocalize with CAL in control cells was lost after stimulation with VIP (300 nM, 30 min), indicating that VIP promotes the dissociation of CFTR and CAL. 3.33% of CFTR and CAL colocalization after VIP treatment compared with 67.25 Ϯ 1.69% in control cells (Fig. 3B) . In cells transfected with NHERF1 siRNAs, intracellular CFTR and CAL colocalization remained strong even after VIP stimulation (Fig. 3C ).
Moreover, a strong reduction in the fluorescence signal observed with the in situ PLA assay after VIP stimulation, compared with control cells, confirms that VIP promotes the dissociation of intracellular CFTR and CAL (Fig. 6A) .
Altogether the data indicate that VIP stimulation favors CFTR/NHERF1 interaction at the cell surface over CFTR/CAL intracellular interaction, which promotes CFTR membrane stability.
ERM phosphorylation by VIP increases its interaction with CFTR.
We investigated the possible role of ERM activation by PKCε phosphorylation after VIP stimulation in CFTR membrane expression. ERM is inactive in the cytoplasm, but upon phosphorylation on serine and threonine residues, by PKC or RhoA kinase, the complex translocates to the cell surface where it exerts its linking activity with the actin cytoskeleton (36) . Stimulation of Calu-3 cells with VIP (300 nM, 1 h) or the general PKC activator PMA (20 nM, 1 h) increased the P-ERM signal observed in immunostaining experiments with a phosphospecific ERM antibody (Fig. 4A ). This was confirmed by immunoblotting of cell lysates (Fig. 4B) . The amount of P-ERM measured by densitometry of scanned immunoblots more than doubled compared with control level after VIP or PMA treatments ( Fig. 4C ; 224.7 Ϯ 82.9% of control, P Ͻ 0.02, and 258.7 Ϯ 52.5% of control, P Ͻ 0.005, for VIP and PMA, respectively). Also, in time-course experiments, a highly significant increase in P-ERM was measured after 30 min of VIP stimulation (Fig. 4, D and E ; 531.8 Ϯ 133.5% of control, P Ͻ 0.004) and remained elevated for 2 h (281.2 Ϯ 24.2% of control, P Ͻ 0.008). Moreover, we found that VIP-dependent phosphorylation of ERM was lost in the presence of PKCε inhibitor peptide EAVSLKPT (Fig. 4, A, F, G) . Interestingly, downregulating ERM expression by transfecting cells with specific siRNAs (56.54202 Ϯ 10.03% of control, P Ͻ 0.001; Fig. 5, A and B) prevented VIP effect, as confirmed by the unchanged CFTR membrane signal. CFTR and CM-Dil signals overlapped by 27.22 Ϯ 1.6 and 28.31 Ϯ 8.48% in control and ERM-siRNA treated cells, respectively, P ϭ 0.881 (Fig. 5,  C-E) . These results show that VIP signaling pathway involves the phosphorylation of ERM by PKCε to stabilize CFTR at the cell membrane.
We also found that VIP stimulation increases the in situ interaction between P-ERM and CFTR and between P-ERM and NHERF1 (Fig. 6B) , suggesting the formation of a complex composed of CFTR, NHERF1, and P-ERM at the cell membrane after VIP stimulation and phosphorylation by PKCε. or NHERF1 specific siRNAs. As shown in Fig. 7A , acute stimulation of CFTR with a cAMP cocktail (150 M cptcAMP ϩ 1 mM IBMXϩ 10 M forskolin) produced a large but transient stimulation of the iodide efflux rate, reaching a peak of efflux after 3 min of stimulation (efflux peak: k ϭ 0.306 Ϯ 0.009 min Ϫ1 ) followed by a rapid decline to basal level. However, when cells were pretreated with VIP for 1 h, the cAMP cocktail elicited a sustained high efflux rate from 2 to 6 min of the efflux, which is comparable to the acute efflux peak measured in VIP-untreated cells (k ϭ 0.254 Ϯ 0.05 min
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Ϫ1
, P Ͼ 0.53). Moreover, the iodide efflux rate remained significantly higher than the baseline for the entire experiment (10 min). Incubating cells with the selective CFTR inhibitor CFTR inh172 eliminated the cAMP-dependent increase in iodide efflux rate (Fig. 7D) .
We repeated the same experiments with cells transfected with specific siRNAs 48 h prior to the experiment to downregulate the expression level of ERM or NHERF1 as before. In these conditions, only a transient efflux peak was obtained by stimulating CFTR with the cAMP cocktail even after VIP treatment (Fig. 7, B and C) . These results show that both ERM and NHERF1 are necessary for sustained increase in CFTR activity induced by VIP treatment.
DISCUSSION
VIP, a 28-amino acid neuropeptide released by intrinsic neurons in the human airways and other exocrine tissues, acts as a physiological agonist for CFTR-dependent secretions, which contribute to the airway innate defense mechanism. After binding to receptors on the basolateral membrane, VIP activates G␣ s -PKA and G␣ q -PKC signaling pathways (49) . In Calu-3 cells, the most widely used model for human airway submucosal glands, stimulation of the G␣ s -PKA signaling cascade activates CFTR function by direct phosphorylation (21, 22) , whereas the G␣ q -PKC signaling pathway mainly regulates CFTR membrane density, also enhancing PKA-dependent activation by phosphorylation (11) . In the present study, we first confirmed the role of PKCε in VIP-mediated increase in CFTR membrane density in Calu-3 cells with a specific inhibitor peptide, showing good correlation with our previous work on human airways and recombinant cells (1, 11, 46) . Actin network and its associated proteins actively regulate the surface stability of many membrane proteins including CFTR (8, 41) . We found here that VIP-stimulated PKCε increased the phosphorylation level of ERM proteins that link CFTR to the actin cytoskeleton, providing surface stability to membrane CFTR. In time-course experiments, VIP stimulation of Calu-3 cells induced ERM phosphorylation in a timely manner consistent with its ability to increase CFTR membrane density previously reported (11) . Also, the positive VIP effect on membrane CFTR density, as well as its ability to phosphorylate ERM, was lost in cells pretreated with the PKCε inhibitor peptide EAVSLKPT, confirming the direct involvement of ERM phosphorylation by PKCε in mediating VIP effect. In the cytoplasm, ERMs exist in inactive monomeric form. Their phosphorylation by PKC on critical threonine residue (T567, T564, T558) in the C-terminus of ezrin, radixin, and moesin, respectively, disrupts the intermolecular interaction in the inactive molecules, unmasking both the F-actin and membrane protein-binding sites (28, 52) , the mechanism thought to enable ERM to link the cytoskeleton to plasma membrane proteins. Many studies demonstrate the role of actin cytoskeleton network and ERM proteins in stabilizing CFTR at the membrane (7, 8, 44) . We used specific siRNA transfection, by electroporation, an efficient method to transfect DNA vectors in epithelial cells (19) , to confirm the role of ERMs and other effectors in VIP signaling cascade. In ERM-siRNA-treated cells, VIP stimulation failed to redistribute CFTR from the cytoplasm to the membrane, indicating the involvement of ERM in VIP signaling cascade.
Unlike other membrane proteins that can bind ERMs directly, the interaction between CFTR and ERM require a bridge protein such as NHERF1, also known as EBP50 (ERMbinding phosphoprotein 50). This scaffolding protein is a good candidate for the following reasons: 1) it enriches at the apical membrane of human airway epithelial cells where both CFTR and ERMs are located (47, 48) , 2) its scaffolding ability to simultaneously bind CFTR with its PDZ domains, ERMs with their ERM-binding domain (EBD), and the complex of PKCε-RACK1 (receptors for activated C kinase) with PDZ1 domain (37-39), 3) its well-known role in the regulation the membrane turnover of CFTR (20, 24) (Fig. 8) . Previous studies demonstrated that NHERF1 regulates CFTR membrane density by interaction with its C-terminal DTRL motif. However, none of them identified the agonist and signaling cascade involved. In the present study, we found that VIP increased CFTR/NHERF1 colocalization and in situ interaction at the cell membrane of Calu-3 cells. Downregulation of NHERF1 expression by specific siRNAs slightly reduced CFTR surface expression as previously reported (30) , without abolishing its membrane localization. Importantly, it prevented VIP ability to increase the membrane density of CFTR. Moreover, in situ PLA experiments demonstrated that VIP stimulation of Calu-3 cells largely increases the interaction of CFTR and NHERF1.
Whether PKCε phosphorylates NHERF1 directly as a result of VIP stimulation or if ERMs activation by phosphorylation induce NHERF1 activation is still unclear. In support of the direct phosphorylation hypothesis, Li et al. (36) provided evidence of the ability of PKC to phoshorylate NHERF1 on two amino acid residues, Ser-339 and Ser-340 in the C-terminal domain, leading to activated NHERF1 interaction with its ligands. Also, NHERF1 interacts with RACK1, which shuttles and holds activated PKCε to the apical domain in proximity to CFTR (37) (38) (39) . All of these studies have used recombinant overexpression of NHERF1, because no phosphospecific antibodies exist for NHERF1. We could not confirm direct phosphorylation of endogenous NHERF1 by VIP but provide evidence that PKCε activation after VIP stimulation increases the phosphorylation level of ERM proteins to form a complex with CFTR. Activation of ERMs by VIP might in turn activate NHERF1 increasing its interaction with CFTR (see Fig. 8 ).
Stimulating Calu-3 cells with VIP reduced the colocalization and interaction between intracellular CFTR and CAL, whereas NHERF1-siRNA transfection resulted in more colocalization between intracellular CFTR and CAL and importantly prevented VIP treatment to reduce CAL and CFTR colocalization. CAL is a Golgi-localized PDZ adaptor protein known as a negative regulator for wild-type CFTR, as well as the F508del-CFTR mutant protein promoting cytoplasmic retention and lysosomal degradation (17, 58) . The reduction of CFTR-CAL localization observed in the present study is consistent with the ability of VIP to redistribute CFTR from the cytoplasm to the membrane. It is known that CAL competes with NHERF1 for the same PDZ-binding motif in the C-terminal of CFTR to regulate its surface expression in opposite manner. The higher binding affinity of NHERF1 PDZ domain to CFTR C-terminus motif explains the ability of wild-type CFTR to avoid premature CAL-dependent lysosomal degradation. Our results show that VIP stimulation regulates this mechanism by promoting NHERF1 while reducing CAL interaction with CFTR by stimulating the PKCε signaling cascade which results in ERMs phosphorylation and its interaction with the activated NHERF1 to anchor CFTR at the membrane in a functional complex (Fig. 8) .
Regulation of chloride secretion by changes in the number of CFTR channels at the cell membrane by modulation of its endocytosis rates and stability has been studied in various cell types but yielded conflicting results. The regulation of this mechanism by physiological agonists such as hormones and neurotransmitters has not yet been clarified. To examine the functional significance of downregulating NHERF1 or ERM, we measured changes in iodide efflux rates. Acute stimulation of CFTR with cAMP produced a large but transient stimulation of the iodide efflux rate, reflecting the direct phosphorylation of CFTR regulatory domain by PKA. However, prolonged stimulation by VIP (30 min to 1 h) produced a sustained activation of CFTR-dependent iodide efflux rate, which is consistent with both CFTR activation by phosphorylation and an increase in the density of active channels at the cell membrane. cAMP stimulation still produced a rapid transient increase in the iodide efflux rate even after downregulation of NHERF1 or ERM by siRNAs transfection. However, the sustained VIP effect was lost, confirming that NHERF1 and ERM are necessary for the regulation of CFTR activity by VIP.
In summary, we report here the identification of the signaling cascade by which the physiological agonist VIP, stabilizes CFTR at the membrane or human airways bronchial serous cells to regulate chloride secretion. Moreover, we could detect the changes in interaction between endogenous CFTR, CAL, NHERF1, and P-ERM proteins after VIP activation directly in Calu-3 cells with the new in situ PLA method, which enables physiological conditions to be maintained compared with traditional coimmunoprecipitations.
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